Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 51
Filter
1.
Br J Cancer ; 100(1): 118-22, 2009 Jan 13.
Article in English | MEDLINE | ID: mdl-19088725

ABSTRACT

Apoptosis is a cell suicide programme characterised by unique cellular events such as mitochondrial fragmentation and dysfunction, nuclear condensation, cytoplasmic shrinkage and activation of apoptotic protease caspases, and these serve as the noticeable apoptotic markers for the commitment of cell demise. Here, we show that, however, the characterised apoptotic dying cancer cells can regain their normal morphology and proliferate after removal of apoptotic inducers. In addition, we demonstrate that reversibility of apoptosis occurs in various cancer cell lines, and in different apoptotic stimuli. Our findings show that cancer cells can survive after initiation of apoptosis, thereby revealing an unexpected potential escape mechanism of cancer cells from chemotherapy.


Subject(s)
Apoptosis , Neoplasms/pathology , Apoptosis/drug effects , Cell Line, Tumor , Cell Survival/drug effects , Depsipeptides/pharmacology , Humans , Neoplasms/drug therapy
2.
Parasite Immunol ; 29(4): 191-9, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17371456

ABSTRACT

The beta-tubulin gene of Trypanosoma evansi (STIB 806) was cloned and expressed in Escherichia coli. The predicted amino acid sequence of T. evansi beta-tubulin shows 100%, 99.8%, 99.1%, and 98.6% homology with T. equiperdum, T. b. brucei, T. cruzi and T. danilewskyi, respectively, but is diverse from that of T. cyclops, showing only 51.6% of homology. Recombinant beta-tubulin was expressed as inclusion bodies in E. coli. It was purified and renatured for immunological studies. Mice immunized with the renatured recombinant beta-tubulin were protected from lethal challenge with T. evansi STIB 806, T. equiperdum STIB 818 and T. b. brucei STIB 940, showing 83.3%, 70% and 76.7% protection, respectively. Serum collected from the rabbit immunized with recombinant beta-tubulin inhibited the growth of T. evansi, T. equiperdum and T. b. brucei in vitro. Serum from mice and rabbits immunized with recombinant beta-tubulin recognized only T. evansi beta-tubulin and not mouse beta-tubulin. The results of this study demonstrated that the recombinant T. evansi beta-tubulin is a potential candidate for the development of a vaccine to prevent animal trypanosomiasis caused by these three trypanosome species.


Subject(s)
Protozoan Vaccines/administration & dosage , Recombinant Proteins/immunology , Trypanosoma/immunology , Trypanosomiasis/prevention & control , Tubulin/immunology , Amino Acid Sequence , Animals , Antibodies, Protozoan/blood , Base Sequence , Cloning, Molecular , Escherichia coli/genetics , Escherichia coli/metabolism , Immunization , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Protozoan Vaccines/genetics , Protozoan Vaccines/immunology , Rabbits , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Trypanosoma/classification , Trypanosoma/genetics , Trypanosoma/metabolism , Trypanosomiasis/immunology , Trypanosomiasis/parasitology , Tubulin/chemistry , Tubulin/genetics , Tubulin/metabolism
3.
Photodiagnosis Photodyn Ther ; 3(4): 247-58, 2006 Dec.
Article in English | MEDLINE | ID: mdl-25046989

ABSTRACT

The photodynamic properties of pyropheophorbide-a methyl ester (MPPa), a semi-synthetic photosensitizer derived from chlorophyll a, were evaluated in a human nasopharyngeal carcinoma HONE-1 cell line. MPPa was non-toxic to the HONE-1. At the concentrations of 0.5-2µM, MPPa-mediated a drug dose-dependent photocytotoxicity in the HONE-1 cells. Confocal microscopy revealed a subcellular localization of MPPa in mitochondria and the Golgi apparatus. MPPa PDT-induced apoptosis was associated with the collapse of mitochondrial membrane potential, release of cytochrome c, the up-regulation of endoplasmic reticulum (ER) stress proteins (calnexin, Grp 94 and Grp78), and the activation of caspases-3 and -9. The photocytotoxicity was reduced by the corresponding specific caspase inhibitors. MPPa PDT-treated HONE-1 cells also up-regulated the gene expression of pro-inflammatory cytokines (IL-1ß, IL-6, and TNF-α) and beta-chemokines (MIP-1ß, MPIF-1, and MPIF-2). These results suggest that the MPPa may be developed as a chlorophyll-based photosensitizer for the treatment of nasopharyngeal carcinoma.

4.
Angiogenesis ; 8(3): 205-16, 2005.
Article in English | MEDLINE | ID: mdl-16328162

ABSTRACT

The major active constituents of ginseng are ginsenosides, and Rg(1) is a predominant compound of the total extract. Recent studies have demonstrated that Rg(1) can promote angiogenesis in vivo and in vitro. In this study, we used a DNA microarray technology to elucidate the mechanisms of action of Rg(1). We report that Rg(1) induces the proliferation of HUVECs, monitored using [(3)H]-thymidine incorporation and Trypan blue exclusion assays. Furthermore, Rg(1) (150-600 nM) also showed an enhanced tube forming inducing effect on the HUVEC. Rg(1) was also demonstrated to promote angiogenesis in an in vivo Matrigel plug assay, and increase endothelial sprouting in the ex vivo rat aorta ring assay. Differential gene expression profile of HUVEC following treatment with Rg(1) revealed the expression of genes related to cell adhesion, migration and cytoskeleton, including RhoA, RhoB, IQGAP1, CALM2, Vav2 and LAMA4. Our results suggest that Rg(1) can promote angiogenesis in multiple models, and this effect is partly due to the modulation of genes that are involved in the cytoskeletal dynamics, cell-cell adhesion and migration.


Subject(s)
Gene Expression Regulation/drug effects , Ginsenosides/metabolism , Neovascularization, Physiologic/physiology , Panax/chemistry , Cell Adhesion/drug effects , Cell Line , Collagen , Cytoskeletal Proteins/metabolism , DNA Primers , Drug Combinations , Ginsenosides/pharmacology , Humans , Laminin , Models, Biological , Neovascularization, Physiologic/drug effects , Oligonucleotide Array Sequence Analysis , Plant Extracts/metabolism , Plant Extracts/pharmacology , Proteoglycans , Reverse Transcriptase Polymerase Chain Reaction , Thymidine/metabolism , Tritium
5.
Crit Rev Clin Lab Sci ; 42(5-6): 473-514, 2005.
Article in English | MEDLINE | ID: mdl-16390682

ABSTRACT

Differentiation therapy of leukemia is the treatment of leukemia cells with biological or chemical agents that induce the terminal differentiation of the cancer cells. It is regarded as a novel and targeted approach to leukemia treatment, based on our better understanding of the hematopoietic process and the mechanisms of its deregulation during leukemogenesis. Clinically, differentiation therapy has been most successful in acute promyelocytic leukemia using all-trans-retinoic acid as the inducer, either alone or in combination with chemotherapy. This review presents evidence that a number of hematopoietic cytokines play important roles in both normal and aberrant hematopoietic processes. In vitro laboratory investigations in the past two decades using well-characterized myeloid leukemic cell lines and primary blast cells from leukemia patients have revealed that many hematopoietic cytokines can trigger lineage-specific differentiation of leukemia cells, which may have important implications in the clinical setting. Moreover, our current understanding of cytokine interactions and the molecular mechanisms of cytokine-induced leukemic cell differentiation will be discussed in the light of recent findings. Finally, ways in which laboratory research on cytokines in the differentiation therapy of leukemia can lead to the improved design of protocols for future clinical applications to leukemia therapy will also be addressed.


Subject(s)
Cell Differentiation , Cytokines/metabolism , Cytokines/therapeutic use , Leukemia/drug therapy , Leukemia/pathology , Animals , Cell Differentiation/drug effects , Cell Transformation, Neoplastic/pathology , Cytokines/pharmacology , Drug Therapy, Combination , Hematopoiesis , Humans , Leukemia/metabolism
6.
J Immunol Methods ; 284(1-2): 177-86, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14736428

ABSTRACT

Specific primers for nine mouse interferon-alpha (IFN-alpha) subtypes, namely, IFN-alpha1, IFN-alpha1-9, IFN-alpha2, IFN-alpha4, IFN-alpha5, IFN-alpha7, IFN-alpha6/8, IFN-alpha11, and IFN-alphaB, were designed and evaluated on Poly(I).Poly(C)-induced and influenza virus-infected L929 cells. Specificity of the primers was confirmed in a cross-polymerase chain reaction (cross-PCR). IFN-alpha1, IFN-alpha1-9, IFN-alpha4, IFN-alpha6/8, IFN-alpha11, and IFN-alphaB were found to be induced in L929 cells 6-9 h after Poly(I).Poly(C) treatment. The amplification of a particular subtype was not biased in the presence of excess of other templates. Differential expression of the IFN-alpha subtypes was observed in influenza A/NWS/33- and B/Lee/40-infected L929 cells. A/NWS/33 virus was found to upregulate the gene expression of IFN-alpha1, IFN-alpha4, IFN-alpha6/8, IFN-alpha11, and IFN-alphaB in L929 cells as early as 6 h after infection. In B/Lee/40-infected L929 cells, only IFN-alpha4 was upregulated. Our results suggest that the designed primers will serve as a useful tool in analyzing the expression of IFN-alpha subtypes in various systems and hence for the evaluation of their function.


Subject(s)
DNA Primers/chemistry , Interferon-alpha/biosynthesis , RNA, Messenger/biosynthesis , Reverse Transcriptase Polymerase Chain Reaction/methods , Animals , Cell Line , DNA Primers/genetics , Fibroblasts , Influenza A virus/immunology , Influenza B virus/immunology , Interferon-alpha/classification , Interferon-alpha/genetics , Mice , RNA, Messenger/genetics
7.
Ann Oncol ; 13(11): 1771-8, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12419750

ABSTRACT

BACKGROUND: We determined the maximum tolerated dose (MTD) and then further evaluated the response rate and safety profile of gemcitabine (Gem) plus doxorubicin (Dox) in chemonaïve patients with advanced hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Dose escalation was tested over four dose levels in each 21-day cycle: level 1 (Gem 1000 mg/m(2) on days 1 and 8, Dox 30 mg/m(2) on day 1), level 2 (Gem/Dox 1250/30), level 3 (Gem/Dox 1250/45) and level 4 (Gem/Dox 1250/60). The MTD was further evaluated in phase II. RESULTS: Patients' characteristics were: 47 men, three women; median age 53 years (range 28-70); Zubrod performance status (PS) scores 0-1 (74%), PS 2 (26%); Okuda stage I (24%) and stage II (76%). Fifteen patients were enrolled in phase I: level 1 (n = 3), level 2 (n = 6), level 3 (n = 6), level 4 (n = 0). Level 2 was identified as the MTD. Dose-limiting toxicities included esophageal bleeding, grade 4 neutropenia and neutropenic fever. Of the 34 patients evaluable for response in phase II (of 35 total), there were four (11.8%) partial responses (95% CI, 0.8% to 22.8%) and six (17.6%) minor responses; nine (26.5%) had stable disease and 15 (44.1%) progressed. Sixteen per cent of patients had a decline of >or=50% in alpha-fetoprotein levels after treatment. Median survival and progression-free survival were 4.6 months (range 0.3-19.2) and 2.5 months (range 0.2-7.8), respectively, for 35 patients. Grade 3/4 hematological toxicities included anemia (45.7%), neutropenia (51.4%), thrombocytopenia (25.7%); febrile neutropenia (11.8%) and non-hematological toxicities were mild to moderate. CONCLUSIONS: Gemcitabine plus doxorubicin produces modest activity and moderate toxicity in this cohort of Chinese patients with advanced HCC.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/pathology , Deoxycytidine/analogs & derivatives , Deoxycytidine/administration & dosage , Doxorubicin/administration & dosage , Liver Neoplasms/drug therapy , Liver Neoplasms/pathology , Maximum Tolerated Dose , Neoplasm Invasiveness/pathology , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Biopsy, Needle , Carcinoma, Hepatocellular/mortality , Deoxycytidine/adverse effects , Dose-Response Relationship, Drug , Doxorubicin/adverse effects , Drug Administration Schedule , Female , Humans , Infusions, Intravenous , Liver Neoplasms/mortality , Male , Middle Aged , Neoplasm Staging , Prognosis , Survival Analysis , Taiwan , Treatment Outcome , Gemcitabine
8.
Biochem Cell Biol ; 80(2): 271-7, 2002.
Article in English | MEDLINE | ID: mdl-11989721

ABSTRACT

The immunomodulation of Narcissus tazetta lectin (NTL) on the induction of gene expression of cytokines in the mouse was studied using specific cytokine primers, total RNA isolated from mouse splenocytes and macrophages, and reverse transcription-polymerase chain reaction (RT-PCR). For comparison, a fungal antimitogenic lectin from Agaricus bisporus (ABL) was used to test and compare the acute (kinetic) induction of cytokine gene expression. NTL was able to induce the expression of IL-1beta, TNF-alpha, and immunoreactive nitric oxide synthase (NOS) in both splenocytes and macrophages in vivo after 10-day consecutive peritoneal injections of 5 mg NTL x kg(-1) x day(-1) in the mouse. Nevertheless, the expression levels of IFN-gamma and TGF-beta were markedly increased in macrophages, and the levels of IL-2 and IL-4 were up-regulated only in splenocytes. From the kinetic pattern of cytokine induction and gene expression, ABL appeared to induce the up-regulation of IL-1beta and TNF-alpha in splenocytes up to 24 h, whereas NTL showed a more sustained effect on the expression of these cytokines in macrophages. While NTL manifested TGF-beta expression at the onset of 12 and 24 h in macrophages and splenocytes, respectively, ABL induced TGF-beta in neither splenocytes nor macrophages. After injection of NTL, stem-cell factor was clearly down-regulated in macrophages at 24 and 48 h but up-regulated in splenocytes at the end of 24 h. The immunopotentiating effect of NTL is quite similar to that of LZ-8, a fungal immunomodulatory lectin isolated from the Chinese premier medicinal mushroom Ganoderma lucidium. However, the mechanism of immunomodulation of NTL still awaits to be elucidated.


Subject(s)
Adjuvants, Immunologic/pharmacology , Cytokines/biosynthesis , Plant Lectins/pharmacology , Animals , Cytokines/genetics , Fungal Proteins/pharmacology , Gene Expression Regulation/drug effects , Gene Expression Regulation/immunology , Injections, Intraperitoneal , Kinetics , Lectins/immunology , Lectins/metabolism , Lectins/pharmacology , Macrophages/drug effects , Macrophages/immunology , Macrophages/metabolism , Male , Mice , Mice, Inbred ICR , Plant Lectins/immunology , Plant Lectins/metabolism , RNA/isolation & purification , Reishi , Reverse Transcriptase Polymerase Chain Reaction , Spleen/cytology , Spleen/drug effects , Spleen/immunology , Spleen/metabolism , Up-Regulation/drug effects
9.
Protein Expr Purif ; 23(1): 33-7, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11570843

ABSTRACT

Surface antigen 1 (SAG1) of Toxoplasma gondii is a good candidate for diagnosis and vaccine development, but recombinant SAG1 produced in Escheichia coli often loses its specific immunogenicity due to the incorrect folding. In the present study, a truncated SAG1 was highly expressed in E. coli as a fusion protein, about 30% of the total protein of the cell lysate. After a simple purification and refolding procedure, purified rSAG1 can be recognized by human Toxoplasma-infective serum, and ELISA kits constructed by rSAG1 can sensitively and specifically detect toxoplasma infection.


Subject(s)
Cloning, Molecular/methods , Protozoan Proteins/chemistry , Protozoan Proteins/immunology , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/immunology , Toxoplasma/immunology , Animals , Antigens, Protozoan/biosynthesis , Antigens, Protozoan/chemistry , Antigens, Protozoan/immunology , Enzyme-Linked Immunosorbent Assay , Escherichia coli/genetics , Humans , Immune Sera/immunology , Protein Folding , Protein Renaturation , Protozoan Proteins/biosynthesis , Recombinant Fusion Proteins/biosynthesis , Toxoplasma/genetics , Toxoplasmosis/diagnosis , Toxoplasmosis/immunology , Transformation, Genetic
10.
J Neural Transm (Vienna) ; 108(4): 397-405, 2001.
Article in English | MEDLINE | ID: mdl-11475007

ABSTRACT

Male C57 mice received 10 consecutive daily intraperitoneal injections of melatonin, 5-methoxytryptamine or 5-methoxytryptophol (5mg/kg body weight). Control mice received the alcoholic saline vehicle. All mice were sacrificed 24 hours after the last injection. Following extraction of RNA from peritoneal exudate cells (PEC) and splenocytes, the level of gene expression was analyzed with the reverse transcription-polymerase chain reaction (RT-PCR). The results revealed that melatonin up-regulated the level of gene expression of transforming growth factor-beta (TGF-beta), macrophage-colony stimulating factor (M-CSF), tumor necrosis factor-alpha (TNF-alpha) and stem cell factor (SCF) in PEC, and the level of gene expression of interleukin-1beta (IL-1beta), M-CSF, TNF-alpha, interferon-gamma (IFN-gamma) and SCF in splenocytes. 5-Methoxytryptamine augmented the level of gene expression of TGF-beta, M-CSF and SCF in PEC, and the level of gene expression of IL-1beta, TNF-alpha, IFN-gamma, M-CSF and SCF in splenocytes. 5-Methoxytryptophol elevated the level of gene expression of TNF-alpha, IL-1beta, TGF-beta and M-CSF in PEC, and the level of gene expression of inducible nitric oxide synthase (iNOS), IL-1beta, M-CSF, TNF-alpha, IFN-gamma and SCF in splenocytes.


Subject(s)
Adjuvants, Immunologic/pharmacology , Cytokines/genetics , Melatonin/pharmacology , 5-Methoxytryptamine/pharmacology , Animals , Anti-Anxiety Agents/pharmacology , DNA Primers , Exudates and Transudates/cytology , Gene Expression/drug effects , Gene Expression/immunology , Indoles/pharmacology , Injections, Intraperitoneal , Interferon-gamma/genetics , Interleukin-1/genetics , Macrophage Colony-Stimulating Factor/genetics , Male , Mice , Mice, Inbred C57BL , Peritoneum/cytology , Pineal Gland/physiology , Spleen/cytology , Stem Cell Factor/genetics , Transforming Growth Factor beta/genetics , Tumor Necrosis Factor-alpha/genetics
11.
Photochem Photobiol ; 72(4): 541-7, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11045727

ABSTRACT

The state of aggregation of the photosensitizer meso-tetrahydroxyphenylchlorin (mTHPC) in both cell free and intracellular environment was elucidated by comparing its absorption and excitation spectra. In methanol, mTHPC existed as monomers and strongly fluoresced. In aqueous solutions such as phosphate-buffered saline (PBS), mTHPC formed nonfluorescent aggregates. Some portion of mTHPC monomerized in the presence of 10% fetal calf serum PBS. In murine myeloid leukemia M1 and WEHI-3B (JCS) cells, cytoplasmic mTHPC were monomeric. By using organelle-specific fluorescent probes, it was found that mTHPC localized preferentially at the mitochondria and the perinuclear region. Photodynamic treatment of mTHPC-sensitized leukemia cells caused rapid appearance of the apoptogenic protein cytochrome c in the cytosol. Results from flow cytometric analysis showed that the release of cytochrome c was especially pronounced in JCS cells, and well correlated with the extent of apoptotic cell death as reported earlier. Electron microscopy revealed the loss of integrity of the mitochondrial membrane and the appearance of chromatin condensation as early as 1 h after light irradiation. We conclude that rapid release of cytochrome c from photodamaged mitochondria is responsible for the mTHPC-induced apoptosis in the myeloid leukemia JCS and M1 cells.


Subject(s)
Leukemia, Myeloid/metabolism , Mesoporphyrins/metabolism , Mitochondria/drug effects , Photosensitizing Agents/metabolism , Animals , Apoptosis/drug effects , Leukemia, Myeloid/pathology , Mesoporphyrins/pharmacokinetics , Mesoporphyrins/toxicity , Mice , Microscopy, Confocal , Mitochondria/metabolism , Photosensitizing Agents/pharmacokinetics , Photosensitizing Agents/toxicity , Spectrometry, Fluorescence , Tumor Cells, Cultured
12.
J Clin Psychopharmacol ; 20(4): 399-403, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10917399

ABSTRACT

Psychosis frequently occurs in women of childbearing potential who may have unplanned pregnancies. Understanding the risk of prenatal antipsychotic exposure can be of benefit in selecting therapies. The authors evaluated the in utero and lactation exposure effects of olanzapine, a novel antipsychotic that is used in treating schizophrenia, bipolar disorder, and other conditions and that may have expanded use in the childbearing population. All prospectively and retrospectively ascertained pregnancy reports were collected as a registry in the Lilly Worldwide Pharmacovigilance Safety Database. Outcomes were available from 23 prospectively ascertained olanzapine-exposed pregnancies. Spontaneous abortion occurred in 13%, stillbirth in 5%, major malformation in 0%, and prematurity in 5%, all within the range of normal historic control rates. There were 11 retrospectively ascertained cases of pregnancy. Two retrospectively ascertained cases of lactation exposure did not suggest infant risk. The early experience with olanzapine use in pregnancy and lactation is encouraging in that no obvious added risk to the fetus or infant was observed. Additional cases of pregnancy and lactation exposure need to be evaluated to determine whether these early findings are representative of the risks of olanzapine exposure to the fetus and infant. At this time, olanzapine should only be used during pregnancy and lactation when the potential benefit justifies the potential risk to the fetus or infant.


Subject(s)
Antipsychotic Agents/adverse effects , Lactation/drug effects , Pirenzepine/analogs & derivatives , Pregnancy Complications/chemically induced , Abnormalities, Drug-Induced/epidemiology , Abortion, Spontaneous/epidemiology , Adult , Benzodiazepines , Clinical Trials as Topic , Female , Humans , Olanzapine , Pirenzepine/adverse effects , Pregnancy , Pregnancy Complications/epidemiology , Prospective Studies , Retrospective Studies
13.
Photochem Photobiol ; 72(1): 114-20, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10911735

ABSTRACT

Subcellular localization of photosensitizers is thought to play a critical role in determining the mode of cell death after photodynamic treatment (PDT) of leukemia cells. Using confocal laser scanning microscopy and fluorescent organelle probes, we examined the subcellular localization of merocyanine 540 (MC540) in the murine myeloid leukemia M1 and WEHI 3B (JCS) cells. Two patterns of localization were observed: in JCS cells, MC540 was found to localize on the plasma membrane and mitochondria; and in M1 leukemia cells, MC540 was found to localize on lysosomes. The relationship between subcellular localization of MC540 and PDT-induced apoptosis was investigated. Apoptotic cell death, as judged by the formation of apoptotic nuclei, was observed 4 h after irradiation in both leukemia cell lines. Typical ladders of apoptotic DNA fragments were also detected by DNA gel electrophoresis in PDT-treated JCS and M1 cells. At the irradiation dose of 46 kJ/m2 (LD90 for JCS and LD86 for M1 cells), the percentage of apoptotic JCS and M1 cells was 78 and 38%, respectively. This study provided substantial evidence that MC540 localized differentially in the mitochondria, and the subsequent photodamage of the organelle played an important role in PDT-mediated apoptosis in myeloid leukemia cells.


Subject(s)
Leukemia, Myeloid, Acute/drug therapy , Photosensitizing Agents/therapeutic use , Pyrimidinones/therapeutic use , Animals , Apoptosis/drug effects , Leukemia, Myeloid, Acute/metabolism , Leukemia, Myeloid, Acute/pathology , Mice , Mitochondria/metabolism , Photochemotherapy , Photosensitizing Agents/pharmacokinetics , Pyrimidinones/pharmacokinetics , Subcellular Fractions/metabolism , Tumor Cells, Cultured
14.
Cancer ; 85(9): 2023-32, 1999 May 01.
Article in English | MEDLINE | ID: mdl-10223245

ABSTRACT

BACKGROUND: Hemolytic uremic syndrome (HUS) is a rare condition that occasionally is reported in cancer patients. Recently it has been observed that gemcitabine rarely may be associated with this condition. METHODS: The manufacturer's safety database and literature were reviewed for any report regarding gemcitabine associated with renal and hematologic abnormalities. Descriptive analysis was used to examine each case for an association between gemcitabine therapy and HUS and to identify its incidence and risk factors. RESULTS: Through December 31, 1997, 12 cases were identified that fit either the clinical (uremia, microangiopathic hemolytic anemia, and thrombocytopenia) or pathologic (renal biopsy) criteria for HUS. There were 7 males (58%) and 5 females (42%) with a median age of 55.5 years (range, 37-73 years). The median duration of gemcitabine therapy was 5.8 months (range, 3.8-13.1 months). Six patients died, five improved, and one patient's outcome was unknown. Among the six deaths, three patients died of cancer progression, one patient died of an unrelated myocardial infarction, and two patients died of HUS or HUS-related complications. For the five patients who improved, treatment was comprised of dialysis, plasmapheresis, splenectomy, or a combination. Attempts to correlate patient demographics, primary malignancy, and cumulative gemcitabine dose failed to identify consistent risk factors in predisposing patients to HUS. Confounding factors were common, including mitomycin-C and/or 5-fluorouracil exposure, advanced stage tumors, or preexisting renal dysfunction. CONCLUSIONS: Based on a patient exposure of 78,800, a crude overall incidence rate of 0.015% (range, 0.008-0.078%) was determined, showing that HUS associated with gemcitabine treatment appears to be rare. Nonetheless, as with other cancer treatments, clinicians should weigh the appropriate risk/benefit ratio in using gemcitabine to treat their patients.


Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Deoxycytidine/analogs & derivatives , Hemolytic-Uremic Syndrome/drug therapy , Adult , Aged , Confounding Factors, Epidemiologic , Deoxycytidine/therapeutic use , Female , Hemolytic-Uremic Syndrome/epidemiology , Humans , Incidence , Male , Middle Aged , Retrospective Studies , Risk Factors , Treatment Outcome , United States/epidemiology , Gemcitabine
15.
Transplantation ; 67(7): 963-71, 1999 Apr 15.
Article in English | MEDLINE | ID: mdl-10221479

ABSTRACT

BACKGROUND: Previous in vivo depletion studies of CD4 and CD8 T cells indicated that different rejection mechanisms operate for proislet allografts and xenografts. The cellular and molecular mechanisms of acute proislet allograft and xenograft rejection have therefore been characterized and directly compared. METHODS: The intragraft cytokine mRNA profile in rejecting BALB/c (H-2d) proislet allografts was analyzed in control, CD4 T cell-depleted, and CD8 T cell-depleted CBA/H (H-2k) recipient mice using semi-quantitative reverse transcriptase-assisted polymerase chain reaction (RT-PCR). The cytokine profiles for proislet allografts and pig proislet xenografts at 3-10 days posttransplant were directly compared and correlated with graft histopathology. RESULTS: Allograft rejection was protracted (2-3 weeks), characterized by infiltrating CD8 T cells and CD4 T cells (no eosinophils) and was associated with a Th1-type CD4 T cell response (IL-2, IFN-gamma, and IL-3 mRNA) and a CD8 T cell-dependent spectrum of cytokine gene expression (IL-2, IFN-gamma, IL-3, and IL-10 mRNA). Xenograft rejection was rapid (6-8 days), involved predominantly CD4 T cells and eosinophils, and in contrast to allografts, exhibited intragraft mRNA expression for the Th2 cytokines IL-4 and IL-5. CONCLUSIONS: Proislet allograft and xenograft rejection differ in the tempo of destruction, phenotype of the cellular response and intragraft profile of cytokine mRNA. The recruitment of eosinophils only to the site of xenorejection correlates with IL4 and IL-5 mRNA expression. These findings suggest that different anti-rejection strategies may need to be developed to optimally target the allograft and the xenograft response.


Subject(s)
Fetal Tissue Transplantation/immunology , Graft Rejection/immunology , Islets of Langerhans Transplantation/immunology , Islets of Langerhans/embryology , Transplantation, Heterologous/immunology , Animals , Cytokines/genetics , Fetus/anatomy & histology , Fetus/metabolism , Graft Rejection/metabolism , Graft Rejection/pathology , Immunohistochemistry , Islets of Langerhans/metabolism , Islets of Langerhans/pathology , Male , Mice , Mice, Inbred BALB C , Mice, Inbred CBA , RNA, Messenger/metabolism , Swine , Transplantation, Homologous/immunology
16.
Life Sci ; 64(12): 1005-11, 1999.
Article in English | MEDLINE | ID: mdl-10210283

ABSTRACT

The immunomodulating action of two mushroom antitumor polysaccharides, polysaccharide-protein complex (PSPC) and lentinan, was elucidated through analysing the expression profile of cytokines during a time course (0 h to 48 h) after their administration. Among the 5 cytokine genes, the induction of a marked increase in the mRNA levels of IL-1alpha, IL-1beta, TNF-alpha, IFN-gamma and M-CSF by PSPC and lentinan was observed in the peritoneal exudate cells and splenocytes. However, the time point of their increased production was different after PSPC and lentinan administration.


Subject(s)
Adjuvants, Immunologic/pharmacology , Agaricales/physiology , Cytokines/genetics , Polysaccharides/pharmacology , RNA, Messenger/analysis , Animals , Interleukin-1/genetics , Lentinan/pharmacology , Male , Mice , Mice, Inbred ICR , Tumor Necrosis Factor-alpha/genetics
17.
Article in English | MEDLINE | ID: mdl-10695787

ABSTRACT

The major surface antigen (P30) of the Toxoplasma gondii was expressed by an insect cell culture system infected with recombinant baculovirus. About 750 microg of purified (95% purity) P30 was obtained from a culture of 10(8) insect Sf21 cells. The recombinant P30 was used to immunize mice to induce immune response. Mice injected with the recombinant protein produced specific humoral and cellular immune responses. Immunization with P30 also prolonged the period of survival of mice infected by Toxoplasma. The average survival time of control group is 13.25+/-1.16 days, but are 16.13+/-2.1 days, 19.50+/-3.21 days, 20.38+/-3.38 days in different immunized groups, respectively.


Subject(s)
Antigens, Protozoan , Baculoviridae/genetics , Baculoviridae/immunology , Cloning, Molecular/methods , Gene Expression Regulation, Viral/genetics , Gene Expression Regulation, Viral/immunology , Protozoan Proteins/genetics , Protozoan Proteins/immunology , Protozoan Vaccines/immunology , Toxoplasma/immunology , Animals , Antibodies, Protozoan/blood , Antibody Formation/immunology , Blotting, Western , Drug Evaluation, Preclinical , Immunity, Cellular/immunology , Mice , Mice, Inbred BALB C , Polymerase Chain Reaction , Transfection
18.
Photochem Photobiol ; 68(4): 545-54, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9796437

ABSTRACT

The photodynamic effects of temoporfin (meso-tetrahydroxyphenylchlorin, mTHPC) and merocyanine 540 (MC540) in murine myeloid leukemia M1 and WEHI 3B (JCS) cells were compared. The mTHPC was found to be more potent and selective. At a lethal dosage of 90% killing (LD90), only 1.3 microM of mTHPC and 4.2 kJ/m2 of light irradiation was required, which was a 20-fold lower drug concentration and 11-fold smaller light dose than that required when using MC540. Meanwhile, three times less, or 15%, of the coincubated erythrocytes were destroyed by mTHPC than by MC540. Confocal micrographs showed that both drugs accumulated diffusely inside the cytoplasm in a very similar fashion, but mTHPC induced a more extensive apoptosis in photosensitized JCS cells. For example, at LD90, mTHPC practically killed all JCS cells via apoptosis and cleaved the DNA to extremely small 150 base-pair fragments. In contrast, among the JCS cells killed by MC540, about 88% died via apoptosis and large DNA fragments were abundant. Relative to MC540, the ability of mTHPC to trigger large-scale and thorough apoptosis in leukemia cells may help explain its potency and selectivity.


Subject(s)
Apoptosis/drug effects , Cell Survival/drug effects , Erythrocytes/drug effects , Light , Mesoporphyrins/toxicity , Photochemotherapy , Photosensitizing Agents/toxicity , Animals , Apoptosis/radiation effects , Cell Survival/radiation effects , Erythrocytes/radiation effects , Leukemia, Experimental , Leukemia, Myeloid , Mice , Pyrimidinones/toxicity , Tumor Cells, Cultured
19.
Chemotherapy ; 43(4): 272-81, 1997.
Article in English | MEDLINE | ID: mdl-9209784

ABSTRACT

The effects of midazolam (MID) on the in vitro growth and differentiation of two murine myeloid leukemia WEHI 3B (JCS) and M1 cells were studied. MID inhibits the proliferation of both M1 and JCS cells in a dose-dependent manner. At the concentration of 10 micrograms/ml, MID was found to induce both monocytic and granulocytic differentiation of the JCS but not M1 cells. Induction of morphological differentiation of the JCS cells was also associated with the enhanced expression of the differentiation antigens Mac-1, F4/80, and Gr-1 for the cells. Results from mRNA phenotyping experiments also indicated that the expression of tumor necrosis factor (TNF-alpha) and neutrophil-specific J11d differentiation marker was significantly upregulated in MID-treated JCS cells. In addition, the phagocytic activity of MID-treated JCS cells was increased towards opsonized yeast cells. Results from this investigation suggested that MID may be used as an inducer for further study on the mechanisms of differentiation in these myeloid leukemia cells.


Subject(s)
Anesthetics, Intravenous/pharmacology , Leukemia, Myeloid/drug therapy , Midazolam/pharmacology , Animals , Cell Differentiation/drug effects , Cell Division/drug effects , Drug Evaluation, Preclinical , Flow Cytometry , Leukemia, Myeloid/pathology , Mice , Phagocytosis/drug effects , Phenotype , RNA, Messenger/genetics
20.
Int J Radiat Oncol Biol Phys ; 38(5): 959-67, 1997 Jul 15.
Article in English | MEDLINE | ID: mdl-9276360

ABSTRACT

PURPOSE: To determine whether patients with early-stage bilateral breast cancer can be treated with definitive irradiation following breast-conserving surgery with acceptable survival, local control, complications, and cosmesis. METHODS AND MATERIALS: During the period 1977-1992, 55 women with Stage 0, I, or II concurrent (n = 12) or sequential (n = 43) bilateral breast cancer were treated with definitive irradiation following breast-conserving surgery. The records of these 55 patients with 110 treated breasts were reviewed for tumor size, histology, pathologic axillary lymph node status, first and overall site(s) of failure, and adjuvant chemotherapy or hormonal therapy. Curves for survival, local control, and regional control were determined. Cosmetic outcome, complication rates, and matching technique were analyzed. The median total radiation dose delivered was 64 Gy (range 42-72) using tangential whole-breast irradiation followed by an electron or iridium implant boost. The tangential fields were matched with no overlap in 40 patients (73%); there was overlap on skin of up to 4 cm in 14 patients (25%); and the matching technique was unknown in 1 patient (2%). The median follow-up for the 12 women with concurrent bilateral breast cancer was 4.0 years. The median follow-up for the other 43 women with sequential cancer was 9.3 and 4.9 years, respectively, after the first and second cancers. RESULTS: For the overall group of 55 patients, the 5- and 10-year overall survival rates were 96% and 94%, respectively, after treatment of the first cancer, and 96% and 92%, respectively, after treatment of the second cancer. The 5- and 10-year actuarial relapse-free survival rates were 90% and 75%, respectively, after treatment of the first cancer, and 83% and 72%, respectively, after treatment of the second cancer. For the 110 treated breast cancers, the 5- and 10-year actuarial local failure rates were 5% and 15%, respectively. Complication rates were: 28% breast edema, 8% arm edema, 4% pneumonitis, 3% cellulitis, 1% rib fracture, and 1% brachial plexopathy; no patient developed matchline fibrosis. For patients with a minimum of 3 years of relapse-free follow-up, the rate of excellent or good cosmetic outcome for 104 treated breasts was 85%. CONCLUSION: Definitive irradiation after breast-conserving surgery is technically feasible for selected patients with concurrent or sequential early-stage bilateral breast cancer. Survival, local control, complication rates, and cosmetic outcomes appear comparable to historical reports of breast conservation treatment for unilateral disease. Bilateral definitive breast irradiation after breast-conservation surgery should be considered an acceptable alternative treatment to bilateral mastectomy for selected patients with concurrent or sequential early-stage bilateral breast cancer.


Subject(s)
Breast Neoplasms/radiotherapy , Breast Neoplasms/surgery , Carcinoma, Ductal, Breast/radiotherapy , Carcinoma, Ductal, Breast/surgery , Neoplasms, Multiple Primary/radiotherapy , Neoplasms, Multiple Primary/surgery , Adult , Aged , Aged, 80 and over , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/mortality , Carcinoma, Ductal, Breast/pathology , Carcinoma, Ductal, Breast/secondary , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Middle Aged , Neoplasm Recurrence, Local , Neoplasm Staging , Neoplasms, Multiple Primary/mortality , Neoplasms, Multiple Primary/pathology , Salvage Therapy , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL
...